Teva

FULVESTRANT

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Teva

Fulvestrant HCPCS:

J9393

HCPCS Code Descriptor:

Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg

Category:

J Code

Fulvestrant NDCs:

00591-5019-02

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Syringe

Route of Administration:

Intramuscular

Fulvestrant CPT Codes:

Potential CPT administration codes for Fulvestrant can be found at the following link.

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

00591-5019-02

About Fulvestrant:

FULVESTRANT is an Oncology drug manufactured by Teva and administered via the Intramuscular route of administration. The J Code: J9393 is aligned to the drug FULVESTRANT.

Fulvestrant is an estrogen receptor antagonist which binds to the receptor in breast cancer cells for the hormone estrogen. After binding to these breast cancer cells, it eventually degrades them. This medication is administered via injection into the muscle. Patient assistance can be found through the Fresenius Kabi patient support site.

ACCESS PRICING AND MORE BY REGISTERING

J9393 Added Date:

January 1, 2023

J9393 Effective Date:

January 1, 2023

J9393 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Fulvestrant billing and coding information.
Fulvestrant patient assistance information can be found through KabiCare at the URL: https://kabicare.us/
FULVESTRANT prescribing information can be found at the link below:
Information regarding FULVESTRANT’s side effects can be found at MedlinePlus